Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents
Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. // Endocrinology & Metabolism Clinics of North America. – URL: https://www.sciencedirect.com/science/article/pii/S0889852926000307?dgcid=rss_sd_all
Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. Endocrinology & Metabolism Clinics of North America. https://www.sciencedirect.com/science/article/pii/S0889852926000307?dgcid=rss_sd_all
“Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents.” Endocrinology & Metabolism Clinics of North America.
@article{article44479,
title = {Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents},
journal = {Endocrinology \& Metabolism Clinics of North America},
url = {https://www.sciencedirect.com/science/article/pii/S0889852926000307?dgcid=rss_sd_all}
}